指南与共识乳腺癌放疗

遗传性乳腺癌管理指南的放射治疗摘要

ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
指南 / 共识 · Pract Radiat Oncol · 2020-05-21

基于ASCO-ASTRO-SSO遗传性乳腺癌管理指南,专家组从58篇文献和6项随机试验中提取局部治疗推荐。BRCA1/2突变者可选保乳治疗,局部控制率与非携带者相似;需讨论双侧乳房切除以应对对侧乳腺癌风险。ATM携带者保乳时不应省略放疗;TP53突变者建议乳房切除,放疗为禁忌,除非局部复发风险显著。

要点

  • BRCA1/2突变新发乳腺癌可考虑保乳治疗,局部控制率与非携带者相似。
  • BRCA1/2突变者对侧乳腺癌风险显著,尤其年轻女性,应讨论双侧乳房切除。
  • TP53突变者建议乳房切除,放疗为禁忌,除非局部复发风险显著。

核心结论

  • BRCA1/2突变乳腺癌患者可考虑保乳治疗,预期局部控制率与非携带者相似。
  • BRCA1/2或中度外显基因突变且适合乳房切除者,保留乳头乳房切除是合理选择。
  • ATM携带者若计划保乳,不应省略放疗;TP53突变者建议乳房切除且放疗为禁忌,除非局部复发风险显著。

研究设计与样本

  • ASCO、ASTRO和SSO召集专家小组,基于系统文献回顾和正式共识流程制定推荐。
  • 共58篇文章符合纳入标准,构成局部治疗推荐的证据基础;另6项系统治疗随机对照试验符合标准。

主要发现

  • BRCA1/2突变者保乳治疗局部控制率与非携带者相似。
  • BRCA1/2突变者对侧乳腺癌风险显著,尤其年轻女性,且同侧乳房新发癌风险较高。
  • BRCA1/2携带者放疗暴露无毒性增加或对侧乳腺癌事件增加的证据。

关键数值与推荐

  • 新发乳腺癌且BRCA1/2突变者可考虑保乳治疗,预期局部控制率与非携带者相似。
  • BRCA1/2或中度外显基因突变且适合乳房切除者,保留乳头乳房切除是合理方法。
  • ATM携带者若计划保乳,不应省略放疗;TP53突变者建议乳房切除且放疗为禁忌,除非局部复发风险显著。

临床怎么用

  • 对BRCA1/2突变新发乳腺癌患者,可提供保乳治疗选项并告知局部控制率与非携带者相似。
  • 与BRCA1/2突变者(尤其年轻女性)讨论双侧乳房切除以应对对侧乳腺癌风险。
  • ATM携带者计划保乳时不应省略放疗;TP53突变者建议乳房切除,放疗仅用于局部复发风险显著者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop a summary of recommendations regarding locoregional management of patients with breast cancer and germline mutations in breast cancer susceptibility genes based on the American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Surgical Oncology Guideline on Management of Hereditary Breast Cancer. METHODS: The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an expert panel to develop recommendations based on a systematic review of the literature and a formal consensus process. A total of 58 articles met the eligibility criteria and formed the evidentiary basis for the locoregional therapy recommendations. Additionally, 6 randomized controlled trials of systemic therapy also met eligibility criteria. RESULTS: A joint evidence-based guideline was developed by a multidisciplinary panel, which has been separately published. From this guideline, the radiation-oncologist authors of the panel extracted pertinent surgical and radiation-specific recommendations of findings that are hereby presented. CONCLUSIONS: Patients with newly diagnosed breast cancer and BRCA1/2 mutations may be considered for breast conserving therapy (BCT), expecting similar rates of local control of the index cancer as noncarriers. The significant risk of contralateral breast cancer in these women (especially younger women), coupled with the higher risk of new cancers in the ipsilateral breast, warrant discussion of bilateral mastectomy. For women with mutations in BRCA1/2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or contralateral breast cancer events from radiation exposure in BRCA1/2 carriers. Patients with mutations in moderate-risk genes should be offered BCT as one choice after appropriate counseling. Radiation therapy should not be withheld in ATM carriers if BCT is planned. For patients with germline TP53 mutations, mastectomy is advised and radiation therapy is contraindicated except for those with a significant risk of locoregional recurrence.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Trombetta MG, Dragun A, Mayr NA, et al. ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer. Pract Radiat Oncol. 2020. PMID: 32471709. doi:10.1016/j.prro.2020.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。